Please use this identifier to cite or link to this item:
Title: GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
Author: Górriz, José Luis
Soler, María José
Navarro González, Juan F.
García Carro, Clara
Puchades, María Jesús
Marco, Luis D’
Martínez Castelao, Alberto
Fernández Fernández, Beatriz
Ortiz, Alberto
Górriz Zambrano, Carmen
Navarro Pérez, Jorge
Gorgojo Martínez, Juan José
Keywords: Malalties cròniques
Malalties del ronyó
Chronic diseases
Kidney diseases
Issue Date: 1-Apr-2020
Publisher: MDPI
Abstract: Type 2 diabetes mellitus (T2DM) represents the main cause of chronic kidney disease (CKD) and end-stage renal disease (ESKD), and diabetic kidney disease (DKD) is a major cause of morbidity and mortality in diabetes. Despite advances in the nephroprotective treatment of T2DM, DKD remains the most common complication, driving the need for renal replacement therapies (RRT) worldwide, and its incidence is increasing. Until recently, prevention of DKD progression was based around strict blood pressure (BP) control, using renin-angiotensin system blockers that simultaneously reduce BP and proteinuria, adequate glycemic control and control of cardiovascular risk factors. Glucagon-like peptide-1 receptor agonists (GLP-1RA) are a new class of anti-hyperglycemic drugs shown to improve cardiovascular and renal events in DKD. In this regard, GLP-1RA offer the potential for adequate glycemic control in multiple stages of DKD without an increased risk of hypoglycemia, preventing the onset of macroalbuminuria and slowing the decline of glomerular filtration rate (GFR) in diabetic patients, also bringing additional benefit in weight reduction, cardiovascular and other kidney outcomes. Results from ongoing trials are pending to assess the impact of GLP-1RA treatments on primary kidney endpoints in DKD.
Note: Reproducció del document publicat a:
It is part of: Journal of Clinical Medicine, 2020, vol. 9, num. 4
Related resource:
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
GorrizJL.pdf1.27 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons